Sail Biomedicines, Inc. ("Sail"), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Laura Sepp-Lorenzino, Ph.D., has joined its Board of Directors. Dr.

The Biochemistry and Molecular Biology Department recently held a poster session, during which students from Bryn Mawr, Haverford, and Swarthmore presented their research findings. Among the ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that ...

Merck recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual meeting.

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...